Trial Profile

A Phase I/II Study of Nivolumab, Ipilimumab and Plinabulin in Patients With Recurrent Small Cell Lung Cancer: Big Ten Cancer Research Consortium. BTCRC-LUN17-127

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 14 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Plinabulin (Primary)
Indications Small cell lung cancer
Focus Adverse reactions; Proof of concept; Therapeutic Use

Most Recent Events

12 Nov 2024 Status changed from active, no longer recruiting to completed.
01 Sep 2024 Results assessing plinabulin in combination with nivolumab and ipilimumab for the treatment of recurrent SCLC published in the Lung Cancer
15 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 Jul 2024.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com